A Phase 1, Open Label, Fixed Sequence, Crossover Study to Investigate the Effect of BAY 2927088 on the Pharmacokinetics of Midazolam in Healthy Participants
Latest Information Update: 17 Jul 2024
At a glance
- Drugs BAY 2927088 (Primary) ; Midazolam
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Bayer
Most Recent Events
- 03 Jul 2024 Status changed from active, no longer recruiting to completed.
- 30 May 2024 Status changed from recruiting to active, no longer recruiting.
- 19 Apr 2024 Status changed from not yet recruiting to recruiting.